We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Serum Albumin Levels Associated with Mortality in Hemodialysis Patients

By LabMedica International staff writers
Posted on 06 Sep 2016
Serum albumin is commonly used as a proxy for nutritional status, as well as a marker of inflammation and a low serum albumin concentration is not only indicative of protein energy wasting in dialysis patients, but it is also a powerful predictor of the mortality risk in this population.

Several clinical conditions are associated with low serum albumin levels in dialysis patients, including infectious and inflammatory diseases, fluid overload, inadequate dialysis, severe co-morbidity, and taste change. More...
Therefore, regular monitoring of serum albumin levels is useful for predicting outcomes in dialysis patients.

Scientists the Chang Gung University College of Medicine (Taoyuan City, Taiwan) and their colleagues included in a study 781 patients who received maintenance hemodialysis (HD) in a large, hospital-facilitated HD center. Five-year medical records (2009–2013) were retrospectively reviewed, and the cut-off level for serum albumin level was set at 3.5 g/dL. Serial haemogram results and biochemical data from the study period were collected and were analyzed retrospectively.

Corrected serum calcium was calculated and all blood samples were analyzed using commercial kits and the Hitachi 7600–210 autoanalyzer (Hitachi Ltd., Tokyo, Japan). Albumin was measured using the bromocresol green method; the normal range was 3.5–5.2 g/dL. The outcome measures included the associations between serum albumin reach rates (defined as the percentage of monthly serum albumin level recordings that were greater or equal to 3.5 g/dL) and time-averaged albumin levels in the first 2-year period with all-cause and cardiovascular mortality in the subsequent 3-year period.

The investigator found that among the 781 patients, 689 patients had higher albumin reach rates and 92 patients had lower albumin reach rates over the 5-year period. Older age and higher prevalence of diabetes were identified in the patients with lower albumin reach rates. Patients with higher albumin reach rates exhibited higher survival rates than those with lower albumin reach rates. In terms of haemogram and biophysical parameters, patients with lower albumin reach rates exhibited significantly lower values for albumin, blood urea nitrogen (BUN), creatinine (Cr), potassium (K), and phosphate (P), and higher levels of corrected serum calcium (Ca), ferritin, and cardiothoracic (CT) ratio than those with higher albumin reach rates.

The authors concluded that their study showed that a higher serum albumin level has a survival benefit in long-term HD patients. An obviously low albumin level should emphasize the need for initiating a management strategy and receiving appropriate medical intervention. The study was published on August 20, 2016, in the journal BMC Nephrology.

Related Links:
Chang Gung University College of Medicine
Hitachi

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.